The Asian Oncology Society 1st Virtual International Conference

 

The Asian Oncology Society 1st Virtual International Conference
M

Systemic Treatment for Advanced HCC: Can Sorafenib Improve PFS/ORR vs. Lenvatinib in Unresectable Disease? Is There OS Benefit With Regorafenib After Sorafenib?

By The Asian Oncology Society 1st Virtual International Conference FEATURING Minsig Choi
By The Asian Oncology Society 1st Virtual International Conference FEATURING Minsig Choi
325 views
February 22, 2021
0 Comments
Login to view comments. Click here to Login

Featured Video

24:44
Indy Hematology Review

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Feat. R. Birhiray

Featured Video

21:09
Exelixis

Primary Analysis and Follow-up Data of a Combination Therapy in 1L a…

Feat. S. Ratnam
Gastrointestinal
18:54
The Asian Oncology Society 1st Virtual International Conference

Genomic Era of CRC Surgery: Total Mesorectal Excision, CME & CVL…

Feat. S. Lee
50:29
The Asian Oncology Society 1st Virtual International Conference

Biomarker Driven and Targeted Therapies in CRC: dMMR/MSI-H, HER2 Ove…

Feat. H. Lenz
16:45
The Asian Oncology Society 1st Virtual International Conference

Systemic Treatment for Advanced HCC: Can Sorafenib Improve PFS/ORR v…

Feat. M. Choi
14:13
The Asian Oncology Society 1st Virtual International Conference

IO in Advanced HCC: Can We Achieve Better ORR With 1L Nivo+Ipi? Does…

Feat. M. Choi
14:19
The Asian Oncology Society 1st Virtual International Conference

NGS for Pancreatobiliary Cancer: Maintenance Olaparib Data in Germli…

Feat. M. Choi
22:56
The Asian Oncology Society 1st Virtual International Conference

Managing Gastric Cancer: Can Genetic Analysis and NGS Help? Should W…

Feat. K. Yoshida
11:02
The Asian Oncology Society 1st Virtual International Conference

Present & Future of Targeted Therapy for Advanced CRC: IO for dM…

Feat. J. Li